Retapamulin
Alternative Names: '833; 275833; 275833AA; Altabax; ALTARGO; SB 275833Latest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antibacterials; Heterocyclic bicyclo compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gram-positive infections; Impetigo; Skin and soft tissue infections
- Discontinued Sinusitis